Abstract
5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.
Publication types
-
Research Support, N.I.H., Intramural
MeSH terms
-
Absorptiometry, Photon
-
Adenine / analogs & derivatives*
-
Adenine / pharmacology
-
Adenine / therapeutic use
-
Adolescent
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Bone Density / drug effects*
-
Child
-
Female
-
HIV
-
HIV Infections / drug therapy*
-
HIV Infections / physiopathology
-
Humans
-
Male
-
Organophosphonates / pharmacology*
-
Organophosphonates / therapeutic use
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Organophosphonates
-
Tenofovir
-
Adenine